Skip to main navigation Skip to search Skip to main content

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

  • C14018 study investigators

Research output: Contribution to journal › Article › peer-review

141   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science